What is XELOXA-A used for?

XELOXA-A is indicated for Treatment of metastatic colorectal cancer.

XELOXA-A is developed by Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD).

What are the side effects of XELOXA-A?

Common side effects include Neurotoxicity, Myelosuppression, Gastrointestinal toxicity.

Last reviewed 2026-04-23 · How we verify

XELOXA-A

Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) · Phase 3 active Small molecule

XELOXA-A is a chemotherapy medication used to treat cancer.

XELOXA-A is a chemotherapy medication used to treat cancer. Used for Treatment of metastatic colorectal cancer.

At a glance

Generic name	XELOXA-A
Sponsor	Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Drug class	Oxaliplatin analog
Target	Thymidylate synthase
Modality	Small molecule
Therapeutic area	Oncology
Phase	Phase 3

Mechanism of action

XELOXA-A works by inhibiting thymidylate synthase, which is involved in DNA synthesis and repair. This leads to the death of rapidly dividing cancer cells.

Approved indications

Treatment of metastatic colorectal cancer

Common side effects

Neurotoxicity
Myelosuppression
Gastrointestinal toxicity

Key clinical trials

Study of Bevacizumab Alone or Combined With Capecitabine and Oxaliplatin as Support Therapy in Metastatic Colorectal Cancer Patients (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results